Definium Therapeutics (DFTX) risk factors, FY2025 10-K

Risks Related to Our Financial Position and Need for Additional Capital

1. 01We have a limited operating history, have not completed any pivotal clinical trials, and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and likelihood of success and viability
2. 02We are a clinical-stage pharmaceutical company and have incurred significant net losses since our inception, and we expect to continue to incur significant net losses for the foreseeable future
3. 03incur additional legal, accounting and other expenses associated with operating as a public company listed in the U.S., including expenses that may result due to securities litigation or shareholder activism
4. 04The terms of our loan agreement place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our operating and financial flexibility38% rewritten
5. 05We have never generated revenue and may never be profitable
6. 06Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve several objectives relating to the discovery, development and commercialization of our product candidates
7. 07attracting, hiring and retaining qualified personnel
8. 08We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts
9. 09the costs of operating as a public company
10. 10Raising additional capital may cause dilution to our existing shareholders, restrict our operations or require us to relinquish rights to our product candidates on unfavorable terms32% rewritten
11. 11adverse effects on existing business operationsNew

Risks Related to the Discovery, Development and Commercialization of our Product Candidates

1. 12We are dependent on the successful development of our product candidates. We cannot give any assurance that any of our product candidates will successfully complete clinical trials or receive regulatory approval, which is necessary before any product candidate can be commercialized49% rewritten
2. 13third-party payors, including government healthcare programs. If we, or any future collaborators, are unable to successfully commercialize our product candidates, we may not be able to generate sufficient revenue to continue our businessNew
3. 14complying with laws and regulations, including laws and regulations applicable to controlled substances92% rewritten
4. 15bodies may require additional data, including with respect to abuse potential of our product candidates, before allowing us to commence a clinical trial or before approving any future marketing application we may submitNew
5. 16or commercial sale, and failure to meet applicable regulatory requirements could lead to enforcement and sanctions by the states in addition to those from the DEA or otherwise arising under federal lawNew
6. 17Our product candidates are controlled substances, the use of which may generate public controversy. Adverse publicity or public perception regarding controlled substances and psychedelics may negatively influence the success of our product candidates
7. 18Drug development is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the preclinical and clinical trial process and we may never successfully progress a product candidate through clinical development
8. 19changes in governmental regulations or administrative actions
9. 20Our clinical trials may fail to demonstrate substantial evidence of the safety and effectiveness of DT120, DT402, or any other product candidates that we may identify and pursue, which would prevent, delay or limit the scope of regulatory approval and commercialization
10. 21Changes in our formulation or components of our formulation of DT120 or DT402 could have a material adverse effect on our business, financial condition and results of operations23% rewritten
11. 22We may not be able to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA or similar regulatory authorities may not permit us to proceed in a timely manner, or at all
12. 23We may not achieve our publicly announced milestones according to schedule, or at all
13. 24The regulatory approval process of the FDA and other comparable foreign authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for any product candidates, our business will be substantially harmed
14. 25the potential risk of our novel product candidates and delivery method, including the use of third-party clinical trial sites and healthcare practitioners
15. 26injunctions or the imposition of civil or criminal penalties
16. 27our reputation may suffer
17. 28Even if we obtain FDA approval for DT120, DT402 or any other product candidates, we may never obtain approval to commercialize any such product candidates outside of the United States, which would limit our ability to realize their full market potential
18. 29There is a variety of risks associated with marketing our product candidates internationally, any of which could materially adversely affect our business
19. 30Research and development of drugs targeting brain health disorders is particularly difficult, which makes it difficult to predict and understand why the drug has a positive effect on some patients but not others
20. 31We depend on enrollment of patients in our clinical trials for our product candidates. If we are unable to enroll patients in our clinical trials, our research and development efforts and business, financial condition and results of operations could be materially adversely affected
21. 32Even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials
22. 33We have never commercialized a product candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize our product candidates on our own or with suitable collaborators
23. 34costs of market access and commercialization above those anticipated by us20% rewritten
24. 35The future commercial success of our product candidates will depend on the degree of market access and acceptance of our product candidates, if approved, among healthcare professionals, patients, healthcare payors, health technology assessment bodies and the medical community at large
25. 36whether our product candidates are designated under physician treatment guidelines or under reimbursement guidelines as a first-line, second-line, third-line or last-line product candidate
26. 37We may become exposed to costly and damaging liability claims, either when testing our product candidates in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims
27. 38the inability to commercialize our product candidates, if approved

Risks Related to Regulatory Approval and other Legal Compliance Matters

1. 39Disruptions at the FDA, including due to a reduction in the FDA’s workforce, inadequate funding for the FDA or a shutdown of the federal government, could prevent the FDA from performing normal functions on which our business relies, which could negatively impact our business
2. 40The distribution of pharmaceutical products is subject to additional requirements and regulations, including licensing, extensive record-keeping, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products91% rewritten
3. 41subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect business in an adverse wayNew
4. 42adequate coverage and reimbursement for our product candidates, if approved, could limit our ability to market those product candidates and decrease our ability to generate revenueNew
5. 43neither experimental nor investigational
6. 44We intend to seek approval to market DT120, DT402 and other product candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions
7. 45Enacted and future legislation may increase the difficulty of commercializing our product candidates and affect the prices we may charge for such product candidates38% rewritten
8. 46In the United States, if all maintenance fees are paid on time, the natural expiration of a patent is generally 20 years from its earliest non-provisional filing date
9. 47We could experience difficulty enforcing our contracts
10. 48Investors in certain jurisdictions may have difficulty in enforcing judgments and effecting the service of process on us
11. 49The increasing use of social media platforms presents new risks and challenges
12. 50The production and sale of our product candidates may be considered illegal or may otherwise be restricted due to the use of controlled substances, which may also have consequences for the legality of investments from foreign jurisdictions
13. 51If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business

Risks Related to Employee Matters, Managing our Growth and Other Risks Related to our Business

1. 52Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees
2. 53We face competition from other biotechnology and pharmaceutical companies and our financial condition and operations will suffer if we fail to effectively compete
3. 54If we are unable to establish sales or marketing capabilities or enter into agreements with third parties to sell or market our product candidates, we may not be able to successfully sell or market our product candidates that obtain regulatory approval
4. 55In order to successfully implement our plans and strategies, we will need to increase the size of our organization, and we may experience difficulties in managing this growth28% rewritten
5. 56improving our operational, financial and management controls, reporting systems and procedures70% rewritten

Risks Related to our Intellectual Property

1. 57Third-party claims or litigation alleging infringement of patents or other proprietary rights, or seeking to invalidate our patents or other proprietary rights, may delay or prevent our development and commercialization efforts24% rewritten
2. 58employees. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplaceNew
3. 59We may not identify relevant patents or may incorrectly interpret the relevance, scope or expiration of a patent, which might adversely affect our ability to develop and market our products
4. 60We may become involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time-consuming and unsuccessful
5. 61We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers
6. 62Obtaining and maintaining our patent protection depends on compliance with various procedural requirements, document submissions, fee payment and other requirements imposed by governmental patent agencies. Our patent protection could be reduced or eliminated for non-compliance with these requirements
7. 63We may not be able to protect our intellectual property rights throughout the world, which could impair our business28% rewritten
8. 64Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates63% rewritten
9. 65Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed56% rewritten
10. 66breach. Our confidential information and trade secrets thus may become known by our competitors in ways we cannot prove or remedyNew
11. 67We may be subject to claims challenging the inventorship of our patent filings and other intellectual property
12. 68If we fail to comply with our obligations in the agreements under which we license intellectual property and other rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business
13. 69If disputes over intellectual property and other rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates and that could harm our business73% rewritten
14. 70Any trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our business

Risks Related to our Dependence on Third Parties

1. 71If we decide to establish collaborations, but are not able to establish those collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans
2. 72We may enter into collaborations with third parties for the development and commercialization of product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates

Risks Related to the Securities Markets and Ownership of our Common Shares

1. 73The price of our common shares is volatile
2. 74general economic, political, industry and market conditions22% rewritten
3. 75Our operating results may fluctuate significantly, which would make our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance
4. 76the changing and volatile global economic and political environment
5. 77Information that is published by third parties, including blogs, articles, message boards and social and other media, has in the past and may in the future include statements not attributable to us and may not be reliable or accurate
6. 78Our business and operations could be negatively affected if we become subject to any securities litigation or shareholder activism, which could cause us to incur significant expense, hinder execution of business and growth strategies and impact our share price
7. 79Actions of activist shareholders against us have been and could be disruptive and costly, may cause uncertainty about the strategic direction of our business, result in litigation, divert management’s and our Board’s attention and resources, and may have an adverse effect on our business and stock price
8. 80Such shareholders may attempt to effect changes in our governance and strategic direction or to acquire control over our Board of Directors or our Company
9. 81Certain provisions of our articles and certain Canadian legislation, together or separately, could discourage or delay certain change in control transactions or shareholder proposals
10. 82We are governed by the corporate laws in British Columbia, Canada which in some cases have a different effect on shareholders than the corporate laws in Delaware, United States
11. 83Our ability to use our net operating loss carryforwards and certain other tax attributes to offset future taxable income and taxes may be limited21% rewritten
12. 84We will be subject to Canadian and United States tax on our worldwide income
13. 85Dispositions of common shares may be subject to Canadian tax and/or United States tax, and dividends on common shares will be subject to Canadian and/or United States taxes
14. 86an estate the income of which is includible in gross income for U.S. federal income tax purposes regardless of its source; or
15. 87We may incur significant tax liabilities as a result of Section 280E of the Code that could negatively impact the results of our operations